New starting dose of avatrombopag for immune thrombocytopenia
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests a modified starting dose of avatrombopag, a medication that helps raise platelet counts, in adults with immune thrombocytopenia (ITP) who have not responded well to first-line steroid treatments. The goal is to see if this new dosing is effective and safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with primary ITP (not caused by another condition).
- Your platelet count is below 30,000 within the last two weeks before joining.
- You have tried at least one round of steroids (like dexamethasone or prednisone) and it didn't work or stopped working, or you had to stop because of side effects.
- You have never taken a TPO-RA medication (like romiplostim, eltrombopag, or avatrombopag) before.
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of two medicines to help raise platelet counts in people with persistent or chronic immune thrombocytopenia (ITP) whose platelets are still low after standard treatments. The goal is to see if this combination works better and is safe.
This study compares two treatments for people with ITP (low platelets) whose condition didn't improve after steroids. One group gets only eltrombopag (a platelet booster pill) and the other gets eltrombopag plus ripertamab (an experimental antibody). The goal is to see if the combination works better at raising platelet levels.
This study tests a combination of multiple drugs given in sequence to adults with newly diagnosed immune thrombocytopenia (ITP), a condition of low platelets. The goal is to see if this approach improves platelet counts and is safe.
This trial tests a new platelet-raising medicine, avatrombopag, in children with ITP who have already tried eltrombopag. It aims to see if switching to avatrombopag can safely increase platelet counts and reduce bleeding.
This trial studies avatrombopag to raise platelet counts in adults with immune thrombocytopenia (ITP) caused by autoimmune conditions. It may help reduce bleeding risk when platelet levels are very low.
This study compares two medicines for adults with newly diagnosed ITP (a low platelet count that can cause bleeding). One medicine is rituximab, which helps the immune system stop attacking platelets, and the other is avatrombopag, which helps the body make more platelets. You may join if your platelet count is very low and standard steroid treatment hasn't worked.
Hear when a new ITP - Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.